Acrivon Therapeutics
Acrivon Therapeutics develops precision oncology medicines using a proprietary proteomics-based platform, with its lead candidate ACR-368 in a Phase 2 trial for multiple tumor types.
Company Overview
Acrivon Therapeutics develops precision oncology medicines that are matched to patients predicted to be sensitive to specific treatments. The company utilizes its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3), to identify the best treatments for individual tumors. Acrivon is headquartered in Watertown, Massachusetts, and also has operations in Lund, Sweden.
Lead Candidate ACR-368
ACR-368 is Acrivon Therapeutics' lead candidate and is a selective small molecule inhibitor targeting CHK1 and CHK2. ACR-368 is currently in a potentially registrational Phase 2 trial across multiple tumor types. The compound has received Fast Track designation from the FDA as a monotherapy for patients with platinum-resistant ovarian or endometrial cancer. Furthermore, the ACR-368 OncoSignature assay has been granted Breakthrough Device designation by the FDA to identify ovarian cancer patients likely to benefit from ACR-368 treatment.
Proprietary Platform: Acrivon Predictive Precision Proteomics (AP3)
Acrivon Therapeutics employs its proprietary Acrivon Predictive Precision Proteomics (AP3) platform to identify which patients will respond to their precision oncology treatments. This proteomics-based patient responder identification system enables Acrivon to tailor treatment plans to individual tumors, enhancing the effectiveness of their therapeutic candidates. AP3 is a cornerstone of the company's approach to developing medicines.
Preclinical Pipeline Programs
In addition to its lead candidate, Acrivon Therapeutics is developing several internally-discovered preclinical stage pipeline programs. Notably among these is ACR-2316, a selective dual WEE1/PKMYT1 inhibitor. These programs are part of Acrivon's broader strategy to create a diverse and effective array of treatments for various cancer types.
Global Operations
Acrivon Therapeutics is headquartered in Watertown, Massachusetts, U.S.A. The company also maintains operations in Lund, Sweden. This global presence allows Acrivon to leverage international expertise and collaboration in its mission to develop precision oncology medicines.